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Abstract Co-crystallization of membrane proteins with anti-
body fragments may emerge as a general tool to facilitate crys-
tal growth and improve crystal quality. The bound antibody
fragment enlarges the hydrophilic part of the mostly hydropho-
bic membrane protein, thereby increasing the interaction area
for possible protein^protein contacts in the crystal. Additionally,
it may restrain £exible parts or lock the membrane protein in a
de¢ned conformational state. For successful co-crystallization
trials, the antibody fragments must be stable in detergents dur-
ing the extended period of crystal growth and must be easily
produced in amounts necessary for crystallography. Therefore,
we constructed a library of antibody Fab fragments from a
framework subset of the HuCAL GOLD0 library (Morphosys,
Munich, Germany). By combining the most stable and well ex-
pressed frameworks, VH3 and VU3, with the further stabilizing
constant domains, a Fab library with the desired properties was
obtained in a standard phage display format. As a proof of
principle, we selected binders with phage display against the
detergent-solubilized citrate transporter CitS of Klebsiella pneu-
moniae. We describe e⁄cient methods for the immobilization of
the membrane protein during selection, for ELISA screening,
and for BIAcore evaluation. We demonstrate that the selected
Fab fragments form stable complexes with native CitS and rec-
ognize conformational epitopes with a⁄nities in the low nano-
molar range.
4 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Membrane proteins are involved in a large variety of bio-
logical functions, including signaling, molecular transport,
electron transport and molecular interactions with soluble or
other membrane-bound ligands. Furthermore, a great fraction
of approved drugs act on membrane proteins, yet their mo-
lecular mechanisms of action are only poorly understood. A
prerequisite for elucidating these natural and drug-induced
mechanisms in detail is access to high-resolution three-dimen-
sional structures. However, only about 75 structures of mem-
brane proteins are currently found in the Protein Data Bank,
as compared to about 23 000 structures of soluble proteins.
This disparity might re£ect the di⁄culties encountered with
the production, the puri¢cation, the stability, and the crystal-
lization of membrane proteins.
Two main limitations in the structural analysis of mem-
brane proteins are, ¢rst, the production of su⁄cient amounts
of pure, solubilized protein that retains its native structure
and, second, the growth of highly ordered crystals with
good di¡raction quality. Evaluation of di¡erent expression
systems and screening of homologous membrane proteins
from di¡erent organisms is unavoidable for optimizing expres-
sion yield and stability. In order to obtain better ordered
crystals or even to allow crystal formation at all, one ap-
proach has been successfully applied for a number of mem-
brane proteins: co-crystallization with antibody fragments
[1^7].
There appear to be two mechanisms by which an antibody
fragment can aid the crystallization of membrane proteins.
First, the bound antibody fragment increases the overall hy-
drophilicity of the complex. This enlarged hydrophilic surface
contributed by the bound antibody fragment can form stable
protein^protein contacts needed for crystallization. This is
especially important for membrane proteins that have only
short loops connecting the transmembrane helices and no ex-
tended extracellular or intracellular domains. Second, binding
of the antibody fragment may stabilize one speci¢c conforma-
tion of the membrane protein and thereby increase the struc-
tural homogeneity of the protein sample. This is particularly
important for membrane proteins with highly £exible regions.
In order to serve as a crystallizing ligand, the antibody frag-
ment has to recognize an epitope that is only present in the
native conformation (and not in the denatured state) of the
membrane protein, bind with high a⁄nity, and form stable
and rigid complexes. As more and more e¡ort is being in-
vested in the structural analysis of membrane proteins, a
fast and reliable system for the generation of such antibody
fragments is needed.
Recombinant antibody technology o¡ers powerful tools to
quickly generate binders against a wide variety of targets
[8^11]. Unlike traditional immunization of laboratory ani-
mals, recombinant antibody technology can accomplish a de-
sired selection within a month. Moreover, the outcome is in-
dependent of the immune response of the animal, and
selection conditions can be adjusted to favor the selection of
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antibodies with the above speci¢cations. However, not all
antibody fragments have biophysical characteristics suitable
for co-crystallization with membrane proteins, particularly
with regard to stability and expression yield. To avoid opti-
mization of each selected antibody fragment prior to crystal-
lization trials, the proper design of the antibody fragment
library is crucial. With a fully synthetic approach, all library
members can be constructed from a template that is stable,
well expressed, and monomeric in solution. Here, we describe
a Fab fragment library that meets these requirements.
A number of recombinant antibody formats exist. Single
antibody domains from camels have been obtained and char-
acterized [12^16] and soluble versions of human V domains
have been made [17]. However, their surface areas are prob-
ably too small to favor additional crystal contacts. In addi-
tion, it remains unclear whether high a⁄nities can be obtained
with these molecules on a routine basis. Fv fragments were the
¢rst antibody fragments to be described [18], but are now
rarely used because of the limited interfacial stability between
heavy and light chain variable domains (VH and VL). Never-
theless, an Fv fragment can be stabilized in complex with its
antigen and successful co-crystallization trials with membrane
proteins have been reported [1^4,7]. Single-chain Fv (scFv)
fragments are most popular [19^21] and quite a number of
them have been crystallized with and without antigen (e.g.
[22^24]). Sometimes a monomer/dimer equilibrium of scFv
fragments exists, depending on the sequence of the individual
antibody, and thus this format is not ideal for crystallization
of di⁄cult targets. It has been shown in a comparative eval-
uation of scFv and Fab fragments that the constant domains
can further stabilize the variable domains in the Fab fragment
(D. Ro«thlisberger et al., manuscript in preparation). The pres-
ence of both constant domains not only increases the inter-
action at the heavy and light chain interface, but they also
optimally place and orient the C-terminal ends of the variable
domains such that tight interface interactions are optimized.
Therefore, the Fab format was chosen for the antibody li-
brary.
In recent years, several selection systems have been devel-
oped for protein^protein interactions, including cell-based sys-
tems such as the protein fragment complementation assay [25]
and the yeast two-hybrid system [26], partially in vitro systems
such as phage display [27] or fully in vitro systems such as
ribosome display [28]. We chose phage display for the present
library because the display of Fab fragments, containing two
unlinked chains, is possible with this system and the selection
step is performed in vitro such that a solubilized membrane
protein can serve as target. Moreover, the phage particle con-
stitutes a robust vehicle and is therefore suited for working in
detergent solutions.
The principle of phage display as used for membrane pro-
teins is illustrated in Fig. 1. DNA encoding the antibody
library is cloned as a fusion to the minor coat protein gIIIp.
The fusion protein is expressed and incorporated into newly
produced phage particles assembled in Escherichia coli. The
antibody fragment is thereby presented on the phage surface
while its encoding gene resides within the phage genome and
is packaged within the phage particle. Antibody-presenting
phages are then subjected to selection, where speci¢c phages
can form complexes with the target in solution. The target/
Fab fragment complexes are captured on magnetic particles,
while non-binding phages are washed away. Bound phages
can be eluted from the immobilized complexes and used to
infect E. coli. The physical linkage between the antibody frag-
ment phenotype and genotype allows the ampli¢cation of spe-
ci¢c antibody fragments displayed on the phage surface. The
recovered clones can initiate a new selection cycle or be fur-
ther analyzed in detail.
To check the performance of the newly assembled library,
we used the citrate carrier CitS, a secondary transporter from
Klebsiella pneumoniae, as a model membrane protein. It is
thought that especially for transporters, which normally do
not possess extensive hydrophilic domains, the binding of
antibody fragments will enhance the formation of protein^
protein contacts. CitS is biochemically well-characterized
[29^32] and has an experimentally determined membrane to-
pology of 11 transmembrane segments [33]. It can be pro-
duced in su⁄cient amounts [34,35], and is functional after
reconstitution into liposomes [30]. This makes CitS a suitable
model membrane protein to establish a system for fast and
reliable selection of antibody fragments used in co-crystalliza-
tion trials.
Fig. 1. Phage display cycle. A library of Fab fragments is displayed
on the surface of phage particles while their genes are cloned into
a phagemid, which is packaged in the phage particle. The phage
library is exposed to the target molecule, the detergent-solubilized
citrate carrier CitS, and phages with the desired speci¢cities form
antibody/antigen complexes. These complexes can be captured on
streptavidin magnetic particles using a biotin tag present on the tar-
get molecule. Unbound phages are washed o¡. The remaining
phages are eluted from the magnetic particles with a pH shift and
used to infect host bacteria. These phages are ampli¢ed and repre-
sent in e¡ect a sub-library, which can be used for another phage
display cycle. Usually after three to ¢ve recursive cycles, single
clones are selected and analyzed.
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2. Materials and methods
2.1. Protein expression and puri¢cation
The citrate carrier CitS from K. pneumoniae was expressed with
either an N-terminal His10 tag or a C-terminal biotin acceptor domain
(BAD) fusion and puri¢ed as described [35]. The biotinylated CitS
fusion consists of full-length CitS (GenBank/EMBL Data Bank, ac-
cession number M83146, aa 1^446) directly fused to BAD of oxalo-
acetate decarboxylase from K. pneumoniae (GenBank/EMBL Data
Bank, accession number J03885, aa 491^595). The gene encoding bio-
tin ligase, birA, was co-expressed from the same plasmid (pMalccit-
SabirA [35]) in E. coli DH5K [36]. For the His-tagged version, which
contains two factor Xa cleavage sites in series, the amino acid se-
quence M-G-(H)10-S-S-G-H-I-E-G-R-H-M-L-D-R-G-S-I-E-G-R was
fused to the ¢rst amino acid of CitS in the vector pET16b (Novagen
[30]). The His-tagged version was expressed in E. coli C43(DE3) [37].
After puri¢cation, CitS was desalted with a PD-10 column (Amer-
sham Biosciences) to remove biotin or imidazole. Protein concentra-
tions were determined by the DC protein assay (Bio-Rad) using bo-
vine serum albumin (BSA) as a standard.
The selected Fab fragments were cloned into the expression plasmid
pMx9 [38], where a mycHis5 tag was introduced at the C-terminus of
the heavy chain. Expression and puri¢cation of soluble Fab fragments
was essentially performed as described [39] with the exception that
cultures were grown in SB medium (20 g tryptone, 10 g yeast extract,
5 g NaCl per liter) and induced at an OD600 of 0.5^0.6. The Fab
fragments were puri¢ed on tandem columns (IMAC/HQ) operated
by a BioCAD system. In this strategy, the eluate from the IMAC
column, which exploits the C-terminal His tag, was directly loaded
onto a HQ anion exchange column in 10 mM Tris, pH 7.5. The Fab
fragments were recovered in the £ow-through, while the contaminat-
ing proteins remained bound to the HQ column. Protein concentra-
tions were determined by measuring the absorbance at 280 nm using
the calculated extinction coe⁄cient [40].
2.2. Phage display
In the selection procedure, about 1011 phages representing the Fab
fragment library were incubated with 100 nM of biotinylated citrate
carrier CitS in 100 Wl CitS bu¡er (20 mM potassium phosphate, pH
7.0, 500 mM NaCl, 20% glycerol, 0.1% dodecylmaltoside) for 1 h at
4‡C. Two independent selections were performed in each round, one
in the absence of citrate and one in the presence of 1 mM citrate. The
complexes were captured with 150 Wl streptavidin magnetic particles
(Roche) and washed 10 times with 1 ml CitS bu¡er at 4‡C. Bound
phages were eluted with 100 Wl of 100 mM glycine, pH 2.2 and then
neutralized with 100 Wl of 1 M Tris, pH 8.0. E. coli TG1 cells [41]
(5 ml, OD600 = 0.8) were infected with the pH-neutralized phages
and then plated on large LB agar plates containing 30 Wg/ml chlor-
amphenicol and 1% glucose. The plates were incubated overnight at
37‡C and the cells were scraped o¡ the next day to inoculate 100 ml of
2UTY (16 g tryptone, 10 g yeast extract, 5 g NaCl per liter) contain-
ing 30 Wg/ml chloramphenicol and 1% glucose. The culture was incu-
bated at 37‡C and at an OD600 = 0.5 the phage library was rescued by
infection with VCS M13 helper phage (Stratagene; multiplicity of
infection V20). The cells were harvested and resuspended in 150 ml
2UYT containing 30 Wg/ml chloramphenicol and 50 Wg/ml kanamycin
and grown overnight at 30‡C for phage production. The phages were
precipitated from the culture supernatant with 25 ml polyethylene
glycol (PEG) solution (20% PEG 6000, 2.5 M NaCl) and redissolved
in 1 ml of high salt phosphate-bu¡ered saline (PBS; 20 mM potassium
phosphate, pH 7.0, 500 mM NaCl). After the fourth round, 30 clones
(15 clones from the selection in the presence and 15 clones from the
selection in the absence of 1 mM citrate) were randomly picked and
analyzed by enzyme-linked immunosorbent assay (ELISA), and the
positive clones were sequenced.
2.3. ELISA
For a ¢rst screening, phage ELISA with single Fab fragments dis-
played on the phage surface was performed. A Maxisorp plate (Nunc)
was coated with neutravidin (Pierce, 66 nM in PBS) overnight and
blocked for 2 h with 3% BSA in PBS at 4‡C. All subsequent incuba-
tions and washes were performed in CitS bu¡er at 4‡C. Biotinylated
citrate carrier CitS (0.27 WM) was immobilized by incubation for 1 h.
About 109 phages displaying selected single clones were preincubated
with either bu¡er (for the binding signal) or 0.27 WM His-tagged, non-
biotinylated CitS (for the speci¢c inhibition of binding signal) for 1 h
on ice and then added to the immobilized CitS. Bound phages were
incubated with anti-M13 antibody horseradish peroxidase (HRP) con-
jugate (Amersham Pharmacia Biotech) and detected with a subse-
quent color reaction (soluble BM blue POD substrate, Roche Diag-
nostics). The color reaction was stopped by adding 1 M HCl to the
sample and the absorbance was measured at 450 nm with an HTS
7000 Plus plate reader (Perkin Elmer).
For the characterization of positive single clones, ELISA in the Fab
format was performed. Fab fragments (500 nM in PBS) were directly
coated on a Maxisorp plate (Nunc) overnight at 4‡C. The plate was
blocked with 3% BSA in PBS for 2 h at 4‡C. All subsequent incuba-
tions and washes were performed in CitS bu¡er at 4‡C. Biotinylated
CitS (100 nM) was preincubated with increasing amounts of the same
Fab fragment as immobilized in the well (0^1 WM) for 1 h on ice and
then added to the well for 1 h. CitS bound to the Fab fragment was
detected with streptavidin^alkaline phosphatase (AP) conjugate
(Roche) in a subsequent color reaction (1.1 mg/ml 4-nitrophenyl phos-
phate (Fluka) in 100 mM Tris, pH 8.8, 100 mM NaCl, 5 mM MgCl2)
by measuring the absorbance at 405 nm with an HTS 7000 Plus plate
reader (Perkin Elmer).
2.4. Equilibrium denaturation measurements
The unfolding of the Fab fragments was followed by the shift of the
emission maximum or the intensity at 330 or 350 nm at each denatur-
ant concentration using £uorescence spectroscopy. All £uorescence
measurements were performed with a PTI Alpha Scan spectro£uorim-
eter (Photon Technologies) using an excitation wavelength of 280 nm
and recording the emission spectra between 320 nm and 365 nm. The
protein concentration was 0.2 WM in all experiments. The Fab frag-
ments were incubated for 1 day at 20‡C in PBS (20 mM potassium
phosphate, pH 7, 150 mM NaCl) containing varying amounts of
guanidine hydrochloride (GdnHCl). We chose this incubation time
arbitrarily, as a slow unfolding of the Fab fragment was reported
previously [42,43]. The exact denaturant concentration in each sample
was determined from its refractive index.
2.5. Determination of dissociation constants by competition BIAcore
Competition BIAcore analysis [44,45] was performed under condi-
tions of mass transport limitation using a CM5 sensor chip (BIAcore)
coated with 2200^2400 resonance units of Fab fragment, immobilized
by amine coupling. The CM5 surface was used as a background con-
trol. Biotinylated CitS was preincubated with di¡erent concentrations
of Fab fragments, acting as competitor of binding, for at least 1 h
prior to injection, and the mass transport-limited rate was measured
as a function of Fab fragment concentration. Each binding^regener-
ation cycle was performed at 10‡C with a constant £ow rate of 20 Wl/
min in 20 mM potassium phosphate, pH 7.0, 500 mM NaCl, 10%
glycerol, 0.1% dodecylmaltoside. In each cycle, bu¡er (50 Wl) was
injected ¢rst to stabilize the baseline, followed by sample injection
(200 Wl), and then 20 Wl glycine (50 mM, pH 3) and 20 Wl 5 M
NaCl were used for regeneration. Data were processed with the soft-
ware Scrubber (D. Myszka, University of Utah, http://www.cores.
utah.edu/Interaction/software.html) and evaluated with BIAevalua-
tion (BIAcore). The slopes of the mass transport-limited rate (robs)
during injection [44,45] were plotted against total Fab fragment con-
centrations to ¢t the dissociation constant using Eq. 1 [46]:
robs ¼ rmaxW 13 1½CitStot W
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where robs is the slope at a given [Fab]tot, rmax is the maximal slope in
the absence of inhibition, [CitS]tot is the total CitS concentration,
[Fab]tot is the total Fab fragment concentration, and KD is the dis-
sociation constant.
2.6. Size exclusion chromatography
Biotinylated CitS fusion protein was incubated with Fab fragment
present in molar excess for 1 h on ice. Samples (100 Wl) of free and
complexed CitS solution were each applied on a Superdex 200 column
(Amersham Biosciences) and the elution pro¢les were monitored by
absorbance at 280 nm and 230 nm.
2.7. Western blot
His-tagged CitS, myc-tagged Fab fragment and prestained protein
marker (broad range; New England Biolabs) were subjected to
sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and Western blot analysis using an Immobilon1-P membrane
(Millipore). The membrane was blocked with 5% milk in PBS and
incubated with 1 WM myc-tagged Fab fragment in 1% milk/PBS for
1 h at room temperature. To detect Fab fragments bound to the blotted
CitS, the membrane was incubated with anti-myc antibody 9B11
(1:1000 in 1% milk/PBS; Cell Signaling Technology) followed by
anti-mouse antibody AP conjugate (1:10 000 in 1% milk/PBS; Sigma)
for 1 h at room temperature. Bound antibodies were detected by a
precipitating color reaction with 5-bromo-4-chloro-indolyl-phosphate
toluidine salt (150 Wg/ml; Fluka) and nitroblue tetrazolium (37.5 Wg/
ml; Fluka) in 100 mM Tris, pH 8.8, 100 mM NaCl, 5 mM MgCl2.
3. Results
3.1. Library construction
Two biophysical features of antibody fragments are consid-
ered to be most critical for successful co-crystallization of
membrane proteins. These are ¢rst the production of antibody
fragments in quantities su⁄cient for co-crystallization trials
and second high thermodynamic stability to ensure that the
antibody fragment remains folded in detergent solution during
both selection and crystal growth. To achieve the best bio-
physical behavior of antibody fragments, both the format and
the framework used in the synthetic antibody fragment library
have to be optimally designed prior to selection against solu-
bilized membrane proteins.
For reasons explained in detail in Section 1, we chose the
Fab format for this purpose. Since the yields obtained with
Fab fragments are frequently lower than with the correspond-
ing scFv fragments [9], we decided to limit the library to var-
iable domains with the best overall biophysical properties.
The choice of the antibody framework is based on a system-
atic evaluation of the biophysical properties of isolated human
consensus variable domains, derived from HuCAL0 [47], and
VH/VL combinations thereof [39]. Ewert et al. [39] have ana-
lyzed and compared the expression behavior, oligomeric state
in solution, and thermodynamic stability of all constructs. A
very strong correlation between the properties of the isolated
domains and their combination in the scFv fragment has been
found. This previous work has shown that VH3/VU3 is the
most favorable scFv fragment with superior properties: the
scFv fragment as well as the isolated VH3 and VU3 domains
show high thermodynamic stability and good expression yield.
The VH3/VU3 scFv fragment is monomeric in solution and
behaves well under all circumstances [39].
We therefore decided to create a VH3/VU3 single framework
phage display library in the Fab format. As a starting point
we used the HuCAL GOLD0 Fab library (Morphosys, Mu-
nich, Germany). While it contains consensus frameworks as in
the original HuCAL0 design [47], the most important mod-
i¢cation in the HuCAL GOLD0 library is that all six com-
plementary determining regions (CDRs) have been diversi¢ed
(S. Urlinger, C. Rothe et al., Morphosys, unpublished). While
CDR-H3 and CDR-L3 are varied as previously described [47],
CDR1 and CDR2 in both heavy and light chains are diversi-
¢ed in a structure-guided approach, in order to keep structur-
al anchor positions intact and to statistically bias the library
towards residues typically found in rearranged sequences. This
was achieved using trinucleotide codons [48] in the gene syn-
thesis. While the HuCAL GOLD0 library uses a disul¢de link
between the Fab fragment and gIIIp of the phage [49], in the
present library, the heavy chain has been fused directly to
gIIIp, as usually done in phage display [38,50,51]. For appli-
cations in crystallography, achieving the best possible bio-
physical properties throughout the library is more important
than maximal diversity, and it is for this reason that we de-
cided to use only a subset of frameworks, namely VH3 and
VU3. About 3U108 independent clones were obtained after
transformation of the ligated library. Sequence analysis of
30 unselected clones showed that, as in the starting HuCAL
GOLD0 library, the diversity and length distribution of the
CDRs corresponded to the design. Ninety percent of all se-
quenced clones were still in-frame and contained no stop co-
don, yielding a high-quality library with a functional size of
2.7U108.
3.2. Selection using phage display
To select conformation-speci¢c Fab fragments, the mem-
brane protein has to be in its native conformation. Selection
on whole cells [52^55] is one possibility to achieve this goal,
since the membrane protein remains in its natural environ-
ment guaranteeing its structural integrity. However, whole
cells represent a very complex antigen source, which can com-
plicate the selection procedure or even make it impossible, if
the membrane protein in question is not well accessible, or if
the expression level is too low [56,57]. Furthermore, only
extracellular epitopes can be targeted. Therefore, pure mem-
brane proteins are required to accelerate and simplify the
selection procedure. After solubilization and puri¢cation the
membrane protein can be used directly (this paper) or recon-
stituted into proteoliposomes [58,59] prior to selection. In the
reconstituted state the biological activity of the membrane
protein can be measured to ensure the native conformation
of the membrane protein. In addition, the detergent problem
is eliminated as it is often a problem to keep the membrane
protein stable in detergent for a long time. However, this
procedure is more time-consuming than direct selection on
solubilized membrane protein and, depending on the method
used, can lead to oriented insertion of the membrane proteins
[60^62], which again hides half of the potential binding sur-
face and makes even the exposed surface less accessible. Fur-
thermore, for some membrane proteins the biological activity
can also be assessed in the detergent-solubilized state [63^68].
Most importantly for the application in structural studies, in
panning experiments with the solubilized membrane protein,
the selection is performed under the same condition as the
crystallization procedure, which ensures a good performance
of the Fab fragments during co-crystallization.
A unique problem in the selections involving solubilized
membrane proteins is their immobilization whilst keeping
them in a native conformation in detergent solution. Direct
immobilization on polystyrene would most probably not re-
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tain the membrane protein in its native conformation, while
immobilization with peptide tags can become signi¢cantly
weakened in detergent or lead to strong non-speci¢c binding
(D. Ott et al., unpublished). Therefore, we initially evaluated
in this work the e⁄cacy of several tags in the presence and
absence of 0.1% dodecylmaltoside in an ELISA format to
ensure that bu¡er conditions do not interfere with binding
(data not shown). The detection of biotin with streptavidin^
AP conjugate (Roche Diagnostics), myc tag with 9B11 anti-
body (Cell Signaling Technology), FLAG tag with M2 anti-
body (Sigma) and His tag with anti-tetra-His antibody (Qia-
gen) were tested, and all bound antibodies were detected with
an anti-mouse IgG^AP conjugate (Sigma). For subsequent
screening, we additionally tested an anti-M13^HRP conjugate
(Roche Diagnostics) that recognizes the major coat protein
gVIIIp of bacteriophage M13. In this comparison, the anti-
M13^HRP conjugate performed best. For biotin and myc tag
detection the signal in detergent reaches about half the signal
in bu¡er, and is still clearly detectable over background sig-
nal. Relatively high background signals were observed for
FLAG tag detection in detergent, and the His tag detection
gives only weak signals compared to the other detection sys-
tems. Therefore, we chose to use an enzymatically added bio-
tin moiety for membrane protein immobilization.
After four rounds of selection, 30 phage clones (15 clones
either in the presence or absence of citrate during selection,
see Section 2) were isolated and screened for binding to CitS
by ELISA (Fig. 2a). To test the speci¢city the binding was
inhibited using the His-tagged version of CitS. Positive clones
(77% of all screened clones) were sequenced. Four di¡erent
Fig. 2. ELISA assays to test the speci¢city of selected clones. a: The initial screening for speci¢c binders is shown with a scheme of the experi-
mental set-up. The binding of single phages, displaying the Fab fragments, to immobilized CitS (binding) or neutravidin (background) was ex-
amined. The binding to immobilized CitS can be inhibited with free antigen as competitor (inhibition). In a subsequent ELISA the functionality
of the free Fab fragments was tested (b). The binding of CitS to the immobilized Fab fragment was inhibited with increasing amounts of free
Fab fragment.
Table 1
Summary of biophysical characterization of the selected Fab fragments
Clone Yield (mg/l culture) Midpoint of unfolding (M) KD (nM)
f3p4 3.1 2.0 4U 2
f4p3 1.2 2.2 n.d.
f4m5 2.5 1.5 n.d.
f4m15 1.7 1.6 27U 7
n.d., not determined.
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sequences were identi¢ed (Fig. 3), three independent clones
and one clone (f4p3) which share the H-CDRs from clone
f3p4 and the L-CDRs from clone f4m5. No speci¢c enrich-
ment of particular clones was observed for the selection in the
presence or absence of citrate.
3.3. Biophysical behavior of selected clones
Routinely, between 2 and 3 mg of pure periplasmically pro-
duced Fab fragment was obtained after a two-column puri¢-
cation from a non-optimized standard 1 l E. coli shake-£ask
culture. Only clone f4p3 was expressed at a slightly lower level
(about 1.2 mg of pure protein) (Table 1). It should be men-
tioned that for reasons of speed, small IMAC columns with
high loading rates were used, leaving room for signi¢cant
yield improvements. Guanidine-induced equilibrium unfolding
curves were measured for all four selected clones (Fig. 4).
Because of the four-domain structure of the Fab fragment
the unfolding is unlikely to be a two-state process, although
a steep transition is observed in all cases. We therefore did not
determine vG values but compared the midpoints of unfolding
as a semiquantitative measure of stability. The midpoints of
unfolding lie between 1.5 M and 2.2 M GdnHCl (Table 1),
consistent with these Fab fragments being highly stable pro-
teins.
3.4. Speci¢city and a⁄nity
To analyze the binding properties of the isolated Fab frag-
ments, we immobilized each Fab fragment directly to the well,
and detected binding of biotinylated CitS to the Fab fragment
with streptavidin^AP fusions. Binding of CitS was observed
to the immobilized selected Fab fragments (Fig. 2b), but not
Fig. 3. The CDR sequences of the selected clones are shown, while the consensus sequences of the framework regions are as described for VH3
and VK3 [47]. Panel a represents CDR1 to CDR3 of the heavy chain and panel b CDR1 to CDR3 of the light chain.
Fig. 4. Overlay of guanidine-induced unfolding curves of the se-
lected Fab fragments. Unfolding was followed by the change in
emission maximum as a function of denaturant concentration at an
excitation wavelength of 280 nm. Clones f3p4 (b) and f4p3 (a)
have three tryptophans in the CDR loops, compared to only one
tryptophan for f4m15 (E) or none for f4m5 (F). Therefore the emis-
sion maximum of the ¢rst two is red-shifted in the native state to
about 341 nm (a), as these tryptophans are already solvent-exposed.
For better comparison of the midpoints of unfolding, the curves are
normalized (b), with the emission maximum at 0 M GdnHCl as 0
and the emission maximum at 4 M GdnHCl as 1. Note that this
normalization makes no assumption about the pre- and post-transi-
tion baselines.
Fig. 5. Determination of the equilibrium dissociation constants KD.
Puri¢ed CitS was mixed with di¡erent concentrations of Fab frag-
ments and incubated for at least 1 h on ice before analysis. Samples
were injected over the sensor chip coated with the corresponding
Fab fragment. The normalized slopes were plotted against the corre-
sponding concentration of soluble Fab fragment. The slopes corre-
late to the amount of uncomplexed CitS. From a ¢t with Eq. 1 (sol-
id line), KD was calculated. The ¢tted lines correspond to KD of
4U 2 nM for the Fab fragment f3p4 (b) and 27U 7 nM for the Fab
fragment f4m15 (a).
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to neutravidin or to an unrelated Fab fragment. Furthermore,
increasing amounts of free Fab fragment in solution inhibited
binding of CitS to the immobilized Fab fragment. This dem-
onstrates that all selected Fab fragments speci¢cally recognize
CitS. Using the same set-up, we also observed that all Fab
fragments compete with each other for binding, indicating
that the Fab fragments bind to the same epitope or overlap-
ping epitopes on the CitS molecule.
To determine the dissociation constants of the binders,
competition BIAcore was performed. The Fab fragments
were covalently linked to the CM5 chip by amine coupling.
Because the Fab fragments were more stable against bu¡er
changes than the membrane protein, this allowed for a rapid
and easy regeneration procedure using low pH and high salt
washes. In contrast to ELISA, BIAcore measurements do not
rely on tags or markers. Therefore, we were able to cross-
check the determined a⁄nity constants with both CitS var-
iants, either the N-terminal His10 tag or the C-terminal BAD
fusion protein. We determined the equilibrium dissociation
constants for two binders, and both Fab fragments showed
high a⁄nities with KD values in the low nanomolar range
(Fig. 5) and no di¡erences in binding a⁄nities to the two
CitS variants were observed (data not shown).
3.5. Complex formation
The tight interaction between CitS and the Fab fragment
was also demonstrated by gel ¢ltration chromatography. Sta-
ble CitS/Fab fragment complexes were formed and eluted in a
single peak (Fig. 6). For comparison, the elution pro¢les of
the free biotinylated CitS (Fig. 6, dashed line) and the com-
plex with molar excess of Fab fragment (Fig. 6, solid line) are
shown. A clear shift towards higher molecular weight is ob-
served for the CitS/Fab fragment complex as compared to free
CitS. The SDS^PAGE analysis of the high molecular weight
peak clearly shows the presence of both CitS and the Fab
fragment (Fig. 6, inset). It can be concluded that the selected
Fab fragments bind to CitS in its detergent-solubilized con-
formation. Moreover, when the binding of the Fab fragments
was tested against SDS^PAGE-denatured CitS by Western
blot analysis, none of the selected Fab fragments was able
to detect CitS (Fig. 7). This indicates that the selected Fab
fragments bind to a conformational epitope.
4. Discussion
Recombinant antibody technology provides a powerful tool
for selecting particular antibody fragments that have the de-
sired speci¢city and functionality from billions of potentially
binding molecules [8^11]. This universally applicable technol-
ogy is also promising for the selection of crystallizing ligands
for membrane proteins. A major advantage of selection tech-
niques in which the binding step occurs in vitro is that the
selection conditions can be varied and adapted to the problem
(for a review of selection strategies see [69]). Selection pressure
and stringency can then be adjusted to generate optimal bind-
ing molecules.
As discussed in previous studies [47,69^71] the library size
and quality and the biophysical properties of the library mem-
bers are all crucial for success when working with di⁄cult
targets or special applications. In order to apply antibody
fragments in co-crystallization experiments with membrane
proteins, the antibody fragments must be stable to remain
folded in detergent solution. Furthermore, rather large
amounts of protein are needed, necessitating good expression
properties. Therefore, based on prior analysis and design of
frameworks [39] and CDRs [47] (S. Urlinger, C. Rothe et al.,
Morphosys, unpublished results), we assembled from a subset
of HuCAL GOLD0 an antibody library in the Fab phage
format whose members have these desired properties. This
high-quality library has a functional size of 2.7U108 indepen-
dent clones. The favorable biophysical properties engineered
into the library guarantee that functionality is maintained
during selection.
We have demonstrated that all selected clones possess the
required characteristics. For crystallization, several milligrams
Fig. 6. Overlay of gel ¢ltration elution pro¢les. Free biotinylated
CitS (dashed line) and biotinylated CitS mixed with excess Fab frag-
ment f4m5 (solid line) were loaded onto a Superdex 200 column.
The CitS/f4m5 complex is shifted towards higher molecular weight
(peak 2) as compared to free CitS (peak 1). A molar mass between
45 kDa and 50 kDa was determined for the Fab fragment (peak 3)
with multi-angle static light scattering (data not shown), despite its
somewhat retarded elution. The corresponding peak fractions were
analyzed on silver-stained polyacrylamide gel (inset). Lane 1: bio-
tinylated CitS peak. The smaller molecular weight band corresponds
to CitS without BAD [34]. Lane 2: CitS/Fab fragment complex
peak. Lane 3: Fab fragment f4m5 peak. The two bands correspond
to the heavy and the light chain of the Fab fragment.
Fig. 7. Test of conformation-speci¢c binding. His-tagged CitS was
subjected to SDS^PAGE and Western blot analysis. The selected
myc-tagged Fab fragments were detected with anti-myc antibody.
No binding of the Fab fragments to the denatured CitS was ob-
served. As a positive control, each corresponding myc-tagged Fab
fragments was subjected to SDS^PAGE and Western blot analysis
as well. For comparison, a Coomassie-stained gel of puri¢ed CitS is
shown on the left hand side with the molecular weight marker indi-
cated.
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of protein are needed, which is now easily achieved from
shake-£ask cultures. This is an advantage because many anti-
body fragments show poor expression behavior, especially if
derived from immunized laboratory animals [72]. In equilib-
rium unfolding experiments, the thermodynamic stabilities of
the selected Fab fragments were measured and the observed
range of stability corresponds well to other stability-engi-
neered or selected antibody fragments [73^75].
Although the library members ful¢ll all basic biophysical
requirements, the binding mode of the antibody fragment to
the membrane protein is also important for successful co-crys-
tallization. An a⁄nity in the low nanomolar range, as deter-
mined for two of the CitS binders, ensures tight interaction
between the antibody fragment and the membrane protein.
Analysis of antibody^antigen complex formation in gel ¢ltra-
tion and Western blot experiments revealed that all selected
Fab fragments recognize a conformational epitope. All of
these binding features together ensure the formation of stable
and rigid complexes. This constitutes a good starting point for
crystallization trials.
In summary, a Fab fragment library was assembled, in
which all members display the biophysical properties desirable
for co-crystallization with membrane proteins. Using phage
display, a fast selection system was established for generating
Fab fragments suitable for co-crystallization. For CitS, three
independent clones with high a⁄nities for conformational epi-
topes were selected, making further a⁄nity or stability matu-
ration unnecessary.
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